Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)
Current research suggests: In summary, berberine is generally safe for kidney health when used responsibly, but long-term data is still limited
Without food in the way, the liposomes can move more easily through the stomach and into the small intestine
It is naturally available in animal products, but deficiencies can occur due to dietary restrictions, malabsorption issues, or certain health conditions
Reference lists of included studies and relevant reviews were screened manually to identify additional eligible studies
"Cardi B topped Taylor Swift: How the rapper dethroned the reigning queen of pop"